17898229|t|Broad-spectrum efficacy across cognitive domains by alpha7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1/2 and CREB phosphorylation pathways.
17898229|a|The alpha7 nicotinic acetylcholine receptor (nAChR) plays an important role in cognitive processes and may represent a drug target for treating cognitive deficits in neurodegenerative and psychiatric disorders. In the present study, we used a novel alpha7 nAChR-selective agonist, 2-methyl-5-(6-phenyl-pyridazin-3-yl)-octahydro-pyrrolo[3,4-c]pyrrole (A-582941) to interrogate cognitive efficacy, as well as examine potential cellular mechanisms of cognition. Exhibiting high affinity to native rat (Ki = 10.8 nM) and human (Ki = 16.7 nM) alpha7 nAChRs, A-582941 enhanced cognitive performance in behavioral assays including the monkey delayed matching-to-sample, rat social recognition, and mouse inhibitory avoidance models that capture domains of working memory, short-term recognition memory, and long-term memory consolidation, respectively. In addition, A-582941 normalized sensory gating deficits induced by the alpha7 nAChR antagonist methyllycaconitine in rats, and in DBA/2 mice that exhibit a natural sensory gating deficit. Examination of signaling pathways known to be involved in cognitive function revealed that alpha7 nAChR agonism increased extracellular-signal regulated kinase 1/2 (ERK1/2) phosphorylation in PC12 cells. Furthermore, increases in ERK1/2 and cAMP response element-binding protein (CREB) phosphorylation were observed in mouse cingulate cortex and/or hippocampus after acute A-582941 administration producing plasma concentrations in the range of alpha7 binding affinities and behavioral efficacious doses. The MEK inhibitor SL327 completely blocked alpha7 agonist-evoked ERK1/2 phosphorylation. Our results demonstrate that alpha7 nAChR agonism can lead to broad-spectrum efficacy in animal models at doses that enhance ERK1/2 and CREB phosphorylation/activation and may represent a mechanism that offers potential to improve cognitive deficits associated with neurodegenerative and psychiatric diseases, such as Alzheimer's disease and schizophrenia.
17898229	52	91	alpha7 nicotinic acetylcholine receptor	Gene	1139
17898229	130	136	ERK1/2	Gene	50689;116590
17898229	141	145	CREB	Gene	12912
17898229	176	215	alpha7 nicotinic acetylcholine receptor	Gene	1139
17898229	217	222	nAChR	Gene	1137
17898229	316	334	cognitive deficits	Disease	MESH:D003072
17898229	338	381	neurodegenerative and psychiatric disorders	Disease	MESH:D019636
17898229	453	521	2-methyl-5-(6-phenyl-pyridazin-3-yl)-octahydro-pyrrolo[3,4-c]pyrrole	Chemical	MESH:C524029
17898229	523	531	A-582941	Chemical	MESH:C524029
17898229	666	669	rat	Species	10116
17898229	689	694	human	Species	9606
17898229	725	733	A-582941	Chemical	MESH:C524029
17898229	800	806	monkey	Species	9527
17898229	835	838	rat	Species	10116
17898229	863	868	mouse	Species	10090
17898229	1031	1039	A-582941	Chemical	MESH:C524029
17898229	1090	1102	alpha7 nAChR	Gene	11441
17898229	1114	1132	methyllycaconitine	Chemical	MESH:C054634
17898229	1136	1140	rats	Species	10116
17898229	1155	1159	mice	Species	10090
17898229	1183	1205	sensory gating deficit	Disease	MESH:D012678
17898229	1329	1370	extracellular-signal regulated kinase 1/2	Gene	50689;116590
17898229	1372	1378	ERK1/2	Gene	50689;116590
17898229	1399	1403	PC12	CellLine	CVCL:0481
17898229	1437	1443	ERK1/2	Gene	26417;26413
17898229	1448	1485	cAMP response element-binding protein	Gene	12912
17898229	1487	1491	CREB	Gene	12912
17898229	1526	1531	mouse	Species	10090
17898229	1580	1588	A-582941	Chemical	MESH:C524029
17898229	1652	1658	alpha7	Gene	28885
17898229	1716	1719	MEK	Gene	5609
17898229	1730	1735	SL327	Chemical	MESH:C424127
17898229	1755	1761	alpha7	Gene	28885
17898229	1777	1783	ERK1/2	Gene	26417;26413
17898229	1926	1932	ERK1/2	Gene	50689;116590
17898229	1937	1941	CREB	Gene	12912
17898229	2032	2050	cognitive deficits	Disease	MESH:D003072
17898229	2067	2109	neurodegenerative and psychiatric diseases	Disease	MESH:D019636
17898229	2119	2138	Alzheimer's disease	Disease	MESH:D000544
17898229	2143	2156	schizophrenia	Disease	MESH:D012559
17898229	Negative_Correlation	MESH:C424127	5609
17898229	Negative_Correlation	MESH:C424127	26413
17898229	Positive_Correlation	MESH:C524029	26413
17898229	Association	MESH:D012559	116590
17898229	Association	MESH:D003072	50689
17898229	Association	MESH:D000544	12912
17898229	Negative_Correlation	MESH:C054634	11441
17898229	Negative_Correlation	MESH:C054634	MESH:C524029
17898229	Negative_Correlation	MESH:C524029	MESH:D012678
17898229	Negative_Correlation	MESH:C424127	26417
17898229	Positive_Correlation	26413	28885
17898229	Association	MESH:D012678	11441
17898229	Association	MESH:D003072	12912
17898229	Positive_Correlation	1139	50689
17898229	Positive_Correlation	26417	28885
17898229	Positive_Correlation	1139	12912
17898229	Negative_Correlation	MESH:C424127	28885
17898229	Positive_Correlation	MESH:C524029	12912
17898229	Positive_Correlation	MESH:C524029	26417
17898229	Association	MESH:D003072	1137
17898229	Association	MESH:D003072	1139
17898229	Association	MESH:D019636	1137
17898229	Association	MESH:D019636	1139
17898229	Association	MESH:D000544	116590
17898229	Association	MESH:D012559	12912
17898229	Association	MESH:D000544	50689
17898229	Positive_Correlation	1139	116590
17898229	Association	MESH:D012559	50689
17898229	Association	MESH:D003072	116590

